Advertisement

Rheumatoid arthritis patients “al nostro cuore”

  • José A. Gómez-Puerta
    Correspondence
    Corresponding author at: Rheumatology Department, Hospital Clinic, Barcelona, Universitat de Barcelona, Barcelona, Spain.
    Affiliations
    Arthritis Unit, Rheumatology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) and University of Barcelona, Barcelona, Spain
    Search for articles by this author
  • Raimon Sanmartí
    Affiliations
    Arthritis Unit, Rheumatology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) and University of Barcelona, Barcelona, Spain
    Search for articles by this author
Published:December 13, 2021DOI:https://doi.org/10.1016/j.ejim.2021.12.006
      Rheumatoid arthritis (RA) constitutes one of the main inflammatory chronic diseases which can lead to important disability and an inflammatory burden including a higher risk of cardiovascular (CV) disease.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hsieh M.J.
        • Lee C.H.
        • Tsai M.L.
        • Kao C.F.
        • Lan W.C.
        • Huang Y.T.
        • Tseng W.Y.
        • Wen M.S.
        • Chang S.H.
        Biologic agents reduce cardiovascular events in rheumatoid arthritis not responsive to tumour necrosis factor inhibitors: a national cohort study.
        Can J Cardiol. 2020; 36: 1739-1746
        • Ljung L.
        • Askling J.
        • Rantapaa-Dahlqvist S.
        • Jacobsson L.
        The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.
        Arthritis Res Ther. 2014; 16 (R127)
        • Wasko M.C.
        • Dasgupta A.
        • Hubert H.
        • Fries J.F.
        • Ward M.M.
        Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis.
        Arthritis Rheum. 2013; 65 (Westlake SL, Colebatch AN, Baird J, Curzen N, Kiely P, Quinn M, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011;50:518–31): 334-342
        • Barnabe C.
        • Martin B.J.
        • Ghali W.A.
        Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis.
        Arthritis Care Res. 2011; 63: 522-529
        • Agca R.
        • Heslinga S.C.
        • Rollefstad S.
        • Heslinga M.
        • McInnes I.B.
        • Peters M.J.
        • et al.
        EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.
        Ann Rheum Dis. 2017; 76: 17-28
        • Dougados M.
        • Soubrier M.
        • Antunez A.
        • et al.
        Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA).
        Ann Rheum Dis. 2014; 73: 62-68
        • Crepaldi G.
        • Scirè C.A.
        • Carrara G.
        • Sakellariou G.
        • Caporali R.
        • Hmamouchi I.
        • Dougados M.
        • Montecucco C.
        Cardiovascular Comorbidities Relate More than Others with Disease Activity in Rheumatoid Arthritis.
        PLoS ONE. Jan 2016; 11e0146991
        • Cacciapaglia F.
        • Spinelli F.R.
        • Piga M.
        • Erre G.L.
        • Sakellariou G.
        • Manfredi A.
        • Viapiana O.
        • Fornaro M.
        • Colella S.
        • Floris A.
        • Mangoni A.A.
        • Castagna F.
        • Vacchi C.
        • Orsolini G.
        • Bugatti S.
        • Cafaro G.
        • Cauli A.
        • Gremese E.
        • Atzeni F.
        • Bartoloni E.
        Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) study group.
        Eur J Intern Med. 2021; https://doi.org/10.1016/j.ejim.2021.10.001
        • Conroy R.M.
        • Pyörälä K.
        • Fitzgerald A.P.
        • Sans S.
        • Menotti A.
        • De Backer G.
        • De Bacquer D.
        • Ducimetière P.
        • Jousilahti P.
        • Keil U.
        • Njølstad I.
        • Oganov R.G.
        • Thomsen T.
        • Tunstall-Pedoe H.
        • Tverdal A.
        • Wedel H.
        • Whincup P.
        • Wilhelmsen L.
        • Graham I.M.
        • SCORE project group
        Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.
        Eur Heart J. Jun 2003; 24: 987-1003
        • Donfrancesco C.
        • Palmieri L.
        • Cooney M.T.
        • Vanuzzo D.
        • Panico S.
        • Cesana G.
        • Ferrario M.
        • Pilotto L.
        • Graham I.M.
        • Giampaoli S.
        Italian cardiovascular mortality charts of the CUORE project: are they comparable with the SCORE charts?.
        Eur J Cardiovasc Prev Rehabil. 2010; 17: 403-409
        • Hippisley-Cox J.
        • Coupland C.
        • Brindle P.
        Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study.
        BMJ. 2017; 357: j2099
        • Goff Jr, D.C.
        • Lloyd-Jones D.M.
        • Bennett G.
        • Coady S.
        • D'Agostino Sr, R.B.
        • Gibbons R.
        • Greenland P.
        • Lackland D.T.
        • Levy D.
        • O'Donnell C.J.
        • Robinson J.G.
        • Schwartz J.S.
        • Shero S.T.
        • Smith Jr, S.C.
        • Sorlie P.
        • Stone N.J.
        • Wilson P.W.F.
        2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 63: 2935-2959
        • Ridker P.M.
        • Buring J.E.
        • Rifai N.
        • Cook N.R.
        Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.
        JAMA. Feb 2007; 297 (https://doi,.org/10.1001/jama.297.6.611): 611-619
        • Solomon D.H.
        • Greenberg J.
        • Curtis J.R.
        • Liu M.
        • Farkouh M.E.
        • Tsao P.
        • Kremer J.M.
        • Etzel C.J.
        Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study.
        Arthritis Rheumatol. 2015; 67: 1995-2003
        • Lacaille D.
        • Avina-Zubieta J.A.
        • Sayre E.C.
        • Abrahamowicz M.
        Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap.
        Ann Rheum Dis. 2017; 76: 1057-1063
        • Yazdani K.
        • Xie H.
        • Avina-Zubieta J.A.
        • Zheng Y.
        • Abrahamowicz M.
        • Lacaille D.
        Ten-year risk of cerebrovascular accidents in incident rheumatoid arthritis: a population-based study of trends over time.
        Rheumatology (Oxford). 2021; 60: 2267-2276
        • Martín-Martínez M.A.
        • Castañeda S.
        • Sánchez-Alonso F.
        • García-Gómez C.
        • González-Juanatey C.
        • Sánchez-Costa J.T.
        • et al.
        CARMA Project Collaborative Group. Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMAtology (CARMA) prospective study-results at 5 years of follow-up.
        Rheumatology (Oxford). 2021; 60: 2906-2915
        • Charles-Schoeman C.
        • Buch M.
        • Dougados M.
        • Bhatt D.
        • Giles J.
        • Vranic I.
        • et al.
        Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors [abstract].
        Arthritis Rheumatol. 2021; 73